⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2580578 | 1.00 | — | — | |
| SCHEMBL3807866 | 1.00 | — | — | |
| SCHEMBL8681978 | 1.00 | — | — | |
| SCHEMBL13084109 | 1.00 | — | — | |
| SCHEMBL13497245 | 1.00 | — | — | |
| SCHEMBL24943522 | 0.85 | TSHR (0.33) | — | |
| SCHEMBL6933813 | 0.85 | TSHR (0.33) | — | |
| SCHEMBL18850030 | 0.85 | TSHR (0.33) | — | |
| SCHEMBL22045699 | 0.85 | TSHR (0.33) | — | |
| SCHEMBL21370154 | 0.85 | TSHR (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3074042-A1 | COMPOSITIONS | Globalacorn Ltd. (GB) | 2016-10-05 | — | — | EP | claimed |
| WO-2015079241-A1 | COMPOSITIONS | GLOBALACORN LTD (GB) | 2015-06-04 | — | — | WO | claimed |
| EP-2854821-A1 | DINUCELOSIDE POLYPHOSPHATES FOR THE TREATMENT OF PAIN | Globalacorn Ltd. (GB) | 2015-04-08 | — | — | EP | claimed |
| WO-2013175231-A1 | DINUCELOSIDE POLYPHOSPHATES FOR THE TREATMENT OF PAIN | GLOBALACORN LTD. (GB) | 2013-11-28 | — | — | WO | claimed |
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2018-10-16 | — | — | US | disclosed |
| WO-2017121328-A1 | METHODS AND COMPOSITIONS FOR REDUCING BODY WEIGHT AND INCREASING GUT MOTILITY | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2017-07-20 | — | — | WO | disclosed |
| EP-3074041-A1 | COMPOSITIONS | Globalacorn Ltd. (GB) | 2016-10-05 | — | — | EP | disclosed |
| EP-3074042-A1 | COMPOSITIONS | Globalacorn Ltd. (GB) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015079241-A1 | COMPOSITIONS | GLOBALACORN LTD (GB) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015079240-A1 | COMPOSITIONS | GLOBALACORN LTD. (GB) | 2015-06-04 | — | — | WO | disclosed |
| EP-2854821-A1 | DINUCELOSIDE POLYPHOSPHATES FOR THE TREATMENT OF PAIN | Globalacorn Ltd. (GB) | 2015-04-08 | — | — | EP | disclosed |
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | GILEAD SCIENCES, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| EP-1411954-B1 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET INC (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-2251015-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | Pharmasset, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| EP-2157095-A2 | Synthesis of beta-L-2-Deoxy nucleosides | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| US-20050059632-A1 | Synthesis of beta-L-2'-deoxy nucleosides | NOVARTIS AG (CH) | 2005-03-17 | — | — | US | disclosed |
| EP-1411954-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | Pharmasset Limited (BB) | 2004-04-28 | — | — | EP | disclosed |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | PHARMASSET, INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2002032920-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET LIMITED (BB) | 2002-04-25 | — | — | WO | disclosed |
| WO-1998000564-A1 | METHODS AND COMPOSITIONS FOR SEQUENCE-SPECIFIC HYBRIDIZATION OF RNA BY 2'-5' OLIGONUCLEOTIDES | DYAD PHARMACEUTICAL CORPORATION (US) | 1998-01-08 | — | — | WO | disclosed |